Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto J Arribas

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Best Practice & Research. Clinical Haematology|March 15, 2017
Methylation patterns in marginal zone lymphomaAlberto J Arribas, Francesco Bertoni
Blood Cancer Discovery|June 26, 2026
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?Alberto J Arribas, Carlo Visco, Francesco Bertoni
British Journal of Haematology|December 28, 2016
Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulationValentina Restelli, Micaela Vagni, Alberto J Arribas, et al.
British Journal of Haematology|October 7, 2025
Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphomaNicolas Munz, Alberto J Arribas, Roberta Bordone Pittau, et al.
Ejhaem|June 8, 2026
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted TherapiesFilippo Spriano, Alberto J Arribas, Fangwen Zhang, et al.
Ejhaem|June 20, 2025
Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma ModelsEugenio Gaudio, Paulina Biniecka, Alberto J Arribas, et al.
Journal of Clinical Medicine|January 21, 2023
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsFrancesca Guidetti, Alberto J Arribas, Giulio Sartori, et al.
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
Hematological Oncology|March 5, 2025
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC SubtypeChiara Tarantelli, Omar Kayali, Elisa Civanelli, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Best Practice & Research. Clinical Haematology|March 15, 2017
Methylation patterns in marginal zone lymphomaAlberto J Arribas, Francesco Bertoni
Blood Cancer Discovery|June 26, 2026
BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?Alberto J Arribas, Carlo Visco, Francesco Bertoni
British Journal of Haematology|December 28, 2016
Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulationValentina Restelli, Micaela Vagni, Alberto J Arribas, et al.
British Journal of Haematology|October 7, 2025
Polatuzumab vedotin and CD79B: A study of efficacy in R-CHOP-resistant diffuse large B-cell lymphomaNicolas Munz, Alberto J Arribas, Roberta Bordone Pittau, et al.
Ejhaem|June 8, 2026
Antimicrobial Peptides Induce Cell Death in Marginal Zone Lymphoma Models Resistant to Targeted TherapiesFilippo Spriano, Alberto J Arribas, Fangwen Zhang, et al.
Ejhaem|June 20, 2025
Novel Flavonoid Derivatives Show Potent Efficacy in Human Lymphoma ModelsEugenio Gaudio, Paulina Biniecka, Alberto J Arribas, et al.
Journal of Clinical Medicine|January 21, 2023
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK InhibitorsFrancesca Guidetti, Alberto J Arribas, Giulio Sartori, et al.
Cancer Medicine|May 14, 2026
Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell LymphomaFilippo Spriano, Luciano Cascione, Chiara Tarantelli, et al.
American Journal of Cancer Research|June 9, 2023
The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma modelsFilippo Spriano, Luca Aresu, Luciano Cascione, et al.
Hematological Oncology|March 5, 2025
Targeting of PIM Kinases Shows Single Agent Efficacy and Synergizes With BCL2 Inhibitors in Diffuse Large B Cell Lymphoma of the ABC SubtypeChiara Tarantelli, Omar Kayali, Elisa Civanelli, et al.
Pageof 4